Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial, PMID: 31104833
Burosumab Therapy in Children with X-Linked Hypophosphatemia, PMID: 29791829
Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children, PMID: 32547492
Burosumab, PMID: 31643797
Burosumab: First Global Approval, PMID: 29679282
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis, PMID: 29947083
Burosumab, PMID: 30000040
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period, PMID: 31165191
Burosumab for the Treatment of Tumor-Induced Osteomalacia, PMID: 33338281
Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease, PMID: 32701599
Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial, PMID: 31369697
Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia, PMID: 32967046
Pharmacoeconomic Review Report: Burosumab (Crysvita): Kyowa Kirin Limited [Internet], PMID: 33301277
Clinical Review Report: Burosumab (Crysvita): (Kyowa Kirin Limited) [Internet], PMID: 33347104
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia, PMID: 31068690
Burosumab for Pediatric X-Linked Hypophosphatemia, PMID: 33970403
Burosumab in X-linked hypophosphatemia: a profile of its use in the USA, PMID: 30459508
Burosumab in tumor-induced osteomalacia: A case report, PMID: 31382017
An Overview of Rickets in Children, PMID: 32647755
CADTH Canadian Drug Expert Committee Recommendation: Burosumab (Crysvita — Kyowa Kirin Limited): Indication: Treatment of X-linked hypophosphatemia [Internet], PMID: 33301278
Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia, PMID: 32133333
Approach to patients with hypophosphataemia, PMID: 31924563
Burosumab treatment of children with X-linked hypophosphataemic rickets, PMID: 31104830
Tumour-induced osteomalacia, PMID: 28703220
Tumor-Induced Osteomalacia, PMID: 32504138
Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD, PMID: 31171590
FGF23, Hypophosphatemia, and Emerging Treatments, PMID: 31485552
X-Linked Hypophosphatemia: A New Era in Management, PMID: 33204932
Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations, PMID: 33112809
Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia, PMID: 29989668
Management of X-linked hypophosphatemia in adults, PMID: 31863781
Antibodies to watch in 2019, PMID: 30516432
FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference, PMID: 32653872
Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia, PMID: 31930323
Burosumab treatment for fibrous dysplasia, PMID: 33984553
Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH), PMID: 30928313
Burosumab: A new drug to treat hypophosphatemic rickets, PMID: 29545670
Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial, PMID: 30638856
Effects of burosumab on osteocalcin and bone mineral density in patient with 15-year history of nonremission tumor-induced osteomalacia initially treated with conventional therapy: Case report, PMID: 33294501
New Therapies for Hypophosphatemia-Related to FGF23 Excess, PMID: 32504139
The evolving therapeutic landscape of genetic skeletal disorders, PMID: 31888683
FGF23 and Associated Disorders of Phosphate Wasting, PMID: 31599133
FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment, PMID: 33295878
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia, PMID: 33484279
First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X-linked Hypophosphatemia, PMID: 30828689
X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment, PMID: 29381780
Correction to: Burosumab in X-linked hypophosphatemia: a profile of its use in the USA, PMID: 31186611
Burosumab for Tumor-Induced Osteomalacia: Not Enough of a Good Thing, PMID: 33950530
Diagnosis and management of pediatric metabolic bone diseases associated with skeletal fragility, PMID: 32692054
Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X-linked Hypophosphatemia, PMID: 34352114
Switching From Active Vitamin d and Phosphate Supplementation to Burosumab Significantly Corrects Lower Limb Malalignment in Pediatric X-Linked Hypophosphatemia., PMID:40511857
Use of burosumab in McCune Albright syndrome: case report and review of literature in mosaic disorders with FGF23 overproduction., PMID:40491596
Toward lean body weight- and ECV-based dosing of burosumab: eliminating apparent sex differences in XLH therapy., PMID:40418279
Burosumab treatment of tumour-induced osteomalacia from a rib lesion., PMID:40379296
Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab., PMID:40358789
Oncogenic rickets diagnosed at age 8 and the risk of persistent rickets: a rare case of pediatric-onset tumor-induced osteomalacia., PMID:40358681
Real-world efficacy and safety of burosumab in tumor-induced osteomalacia: case series from an early access program., PMID:40329993
Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort., PMID:40323576
Real-World Effectiveness of Burosumab Versus Oral Phosphate and Active Vitamin D in Adults With X-Linked Hypophosphatemia., PMID:40314226
Burosumab treatment of a child with McCune-Albright syndrome/polyostotic fibrous dysplasia: challenges and benefits., PMID:40297189
A Child with Cutaneous-Skeletal Hypophosphatemia Syndrome Caused by a Mosaic HRAS Mutation: Outcome of Treatment with Anti-FGF23 Antibody., PMID:40295341
The Diagnosis and Therapy of XLH., PMID:40295317
Advancing patient evidence in XLH (APEX): rationale and design of a real-world XLH global data unification program., PMID:40260280
X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline., PMID:40243526
Acral Mesenchymal Tumor Leading to Tumor-Induced Osteomalacia: Case Report and Literature Review., PMID:40201463
Tumor-induced rickets/osteomalacia (TIO): diagnostic pitfalls and therapeutic options., PMID:40156290
Office Blood Pressure and Obesity in Children with X-Linked Hypophosphatemia., PMID:40152980
Methodology for the international working group clinical practice guidelines on X-linked hypophosphatemia in children and adults., PMID:40119067
Two Cases of Tumor-induced Osteomalacia Resulting in Surgical Resection During Burosumab Therapy., PMID:40058863
X-Linked Hypophosphataemia and Burosumab: A Systemic Disease With a New Treatment., PMID:40012305
X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline., PMID:39960858
Burosumab Treatment in a Girl With Cutaneous Skeletal Hypophosphatemia Syndrome: 2-Year Follow-Up., PMID:39925163
XLH Matters: an evolving programme to discuss new advances and share clinical experiences to improve patient outcomes., PMID:39901153
Combined Treatment With Leuprolide Acetate and Burosumab in X-linked Hypophosphatemia and Precocious Puberty: A Therapeutic Response., PMID:39896952
Case report: Prolonged and severe hungry bone syndrome after parathyroidectomy in X-linked hypophosphatemia., PMID:39839473
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia., PMID:39814982
Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia., PMID:39787354
Treatment Advances in Tumor-Induced Osteomalacia., PMID:39755803
Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients With X-Linked Hypophosphatemia., PMID:39715351
Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study., PMID:39687707
Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH)., PMID:39679164
In-depth clinical characterization of intravenous iron infusion-induced hypophosphatemic osteomalacia and its resolution., PMID:39659775
Use of Whole-Exome Sequencing and Pedigree Analysis to Identify X-linked Hypophosphatemia in Saudi Arabian Families., PMID:39659542
Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patients., PMID:39624115
Use of burosumab in two young children with X-linked hypophosphataemic rickets in Hong Kong: two case reports., PMID:39587955
Erratum: X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteriscs of a single-center pediatric cohort in North America before and after burosumab., PMID:39564381
Acquired hypophosphatemic osteomalacia: case series from a Peruvian referral center (1999-2023)., PMID:39560849
Real-World Clinical and Healthcare Resource Burden Among Burosumab-Naïve Patients With Familial Hypophosphatemia., PMID:39539413
Tertiary hyperparathyroidism in two paediatric patients with X-linked hypophosphatemia during Burosumab treatment., PMID:39515508
Analytical interference of Burosumab therapy on intact fibroblast growth factor 23 (iFGF23) measurements using an immunoassay: preliminary evaluation., PMID:39494895
Association between work productivity and characteristics of adults with X-linked hypophosphatemia: an analysis of the XLH disease monitoring program., PMID:39464774
Model-Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor-Induced Osteomalacia., PMID:39446135
Burosumab, a Transformational Treatment in a Pediatric Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome., PMID:39416269
Effective bone healing after corrective osteotomy in a patient with FGF23-related hypophosphatemic disease using short-term burosumab treatment., PMID:39375070
Pharmacodynamic Exposure-Response Analysis of Fracture Count Data Following Treatment with Burosumab in Patients with XLH., PMID:39344278
Improvement of Fibrous Dysplasia After Burosumab Therapy in a Pediatric Patient with McCune-Albright Syndrome: A Case Report., PMID:39303050
Meta-analysis and systematic review: burosumab as a promising treatment for children with X-linked hypophosphatemia., PMID:39211452
Commentary on: The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience., PMID:39162952
For research use only. Not for human or drug use.
